Structure Therapeutics (GPCR) Total Current Liabilities (2022 - 2026)
Quarterly Total Current Liabilities rose 56.18% to $57.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $57.0 million through Mar 2026, up 56.18% year-over-year, with the annual reading at $63.3 million for FY2025, 75.69% up from the prior year.
Structure Therapeutics' Total Current Liabilities history spans 5 years, with the latest figure at $57.0 million for Q1 2026.
- Total Current Liabilities came in at $57.0 million for Q1 2026, down from $63.3 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $63.3 million in Q4 2025 to a low of $11.0 million in Q1 2023.
- The 5-year median for Total Current Liabilities is $29.1 million (2023), against an average of $32.3 million.
- The largest YoY upside for Total Current Liabilities was 114.38% in 2024 against a maximum downside of 45.6% in 2024.
- Structure Therapeutics' Total Current Liabilities stood at $13.0 million in 2022, then skyrocketed by 90.16% to $24.7 million in 2023, then soared by 45.6% to $36.0 million in 2024, then surged by 75.69% to $63.3 million in 2025, then decreased by 9.96% to $57.0 million in 2026.
- Per Business Quant, the three most recent readings for GPCR's Total Current Liabilities are $57.0 million (Q1 2026), $63.3 million (Q4 2025), and $57.5 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 16.35 Mn |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | 1.70 Mn |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 636.40 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | 66.94 Mn |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | 13.42 Mn |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 3.88 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 5.11 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 1.35 Bn |
| 10 | Structure Therapeutics | 8.43 Bn | 8.43 Bn | - | 56.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 56.98 Mn |
| Dec 31, 2025 | 63.29 Mn |
| Sep 30, 2025 | 57.53 Mn |
| Jun 30, 2025 | 39.03 Mn |
| Mar 31, 2025 | 36.49 Mn |
| Dec 31, 2024 | 36.02 Mn |
| Sep 30, 2024 | 33.43 Mn |
| Jun 30, 2024 | 22.66 Mn |
| Mar 31, 2024 | 23.59 Mn |
| Dec 31, 2023 | 24.74 Mn |
| Sep 30, 2023 | 20.09 Mn |
| Jun 30, 2023 | 15.01 Mn |
| Mar 31, 2023 | 11.00 Mn |
| Dec 31, 2022 | 13.01 Mn |